开源证券给予华东医药买入评级，公司信息更新报告：创新药收入快速增长，多产品步入收获期

Group 1 - The core viewpoint of the article is that Huadong Medicine (000963.SZ) is rated as a "buy" by Open Source Securities due to its rapid growth in innovative drug revenue and the establishment of a product matrix [2] - The company is seen as a representative of "pharma valuation reshaping," indicating an accelerated transformation towards innovation [2] Group 2 - The report highlights the key reasons for the buy rating, which include the fast growth of innovative drug income and the ongoing development of a diverse product portfolio [2] - The transformation towards innovation is emphasized as a significant factor in the company's future prospects [2]